Reports Q3 revenue $994.2M, consensus $990.71M. “Dexcom’s (DXCM) third quarter results were in line with our expectations as our team responded quickly to the business dynamics that emerged earlier ...

Dexcom’s Stelo continuous glucose monitor (CGM) for those with Type 2 diabetes is starting to use generative AI to write weekly reports with “more personalized tips, recommendations, and education ...

DexCom reports quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue comes in at $994.2 million, which beat the analyst consensus estimate ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an ...

The accompanying press release dated February 13, 2025 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating ...

Dexcom shares tumbled nearly 45% after the diabetes tech titan reported a 2Q24 miss and cut guidance. The San Diego, CA-based company posted $1.04 billion in revenue which was $33 million lower than ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

Stream Connecticut News for free, 24/7, wherever you are. Stelo is an over-the-counter CGM that pokes through the skin to measure real-time blood sugar levels. The sensor launched in August and can be ...